Literature DB >> 32732679

Advances in Classification and Treatment of Non-Hodgkin Lymphoma: Mantle Cell.

Simon Rule1, Sophie Johns2.   

Abstract

Mantle cell lymphoma is a rare, aggressive, and largely incurable form of non-Hodgkin lymphoma. There are a number of well-characterized prognostic features but nothing that can help guide therapy. Treatment with chemotherapy is generally effective in the short term, but relapse is inevitable and subsequent treatment is challenging. The use of Bruton tyrosine kinase inhibitors, however, has transformed practice. These agents are highly active in relapsed disease and are very well-tolerated drugs. Chemotherapy-free combinations using Bruton tyrosine kinase inhibitors look very exciting and will likely evolve to be part of frontline care in the future.

Entities:  

Mesh:

Year:  2020        PMID: 32732679     DOI: 10.1097/PPO.0000000000000462

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  1 in total

1.  MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway.

Authors:  Jingjing Yuan; Qing Zhang; Shengsheng Wu; Suran Yan; Ran Zhao; Yajuan Sun; Xiaoxu Tian; Keshu Zhou
Journal:  Onco Targets Ther       Date:  2021-03-02       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.